On September 20, 2024, the U.S. Food and Drug Administration (FDA) approved the first influenza (flu) vaccine for at‑home use. The vaccine, ...

The FDA's proposal comes more than a year after the agency's outside advisers voted against continued use of the ingredient, called oral phenylephrine, citing concerns with the initial data used ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

The Food and Drug Administration’s (FDA) recent authorization of FluMist for at-home administration marks the beginning of a new chapter in vaccine access and delivery. Before now, self ...

Per the FDA, nitrosamine impurities "may increase the risk of cancer if people are exposed to them above acceptable levels and over long periods of time." However, it added, "a person taking a ...

Thousands of bottles of a commonly prescribed antidepressant drug have been recalled by the FDA because they were found to contain a suspected cancer-causing chemical. Over 7,100 bottles of ...

FluMist, the nasal flu vaccine spray, was approved in September by the U.S. Food and Drug Administration for at-home use starting in fall 2025. Currently, it can only be administered by a healthcare ...

SATURDAY, Oct. 26, 2024 (HealthDay News) -- Now that the U.S. Food and Drug Administration has approved the at-home use of ...

Eli Lilly holds the patent for tirzepatide, and while the FDA doesn't enforce patents, the agency does regulate whether pharmacies are making unauthorized copies of FDA-approved drugs — a limit ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding ...

The FDA has agreed to review its decision to remove Eli Lilly’s LLY tirzepatide — the active ingredient used in diabetes drug Mounjaro and obesity drug Zepbound — from its shortage list.